A B-cell-dampening antibody cut relapses in IgG4-related disease

A weekly injectable antibody, obexelimab, roughly halved the risk of a relapse in IgG4-related disease and let patients come off steroids in a phase 3 trial — a meaningful result for a rare condition that, until now, has had no drug approved to treat it [s1]. The trial, called INDIGO, is the kind of rigorous randomised evidence this disease has lacked; it is also funded by the drug's developer, and its main comparison was against placebo after a deliberate steroid withdrawal, which shapes how the benefit should be read [s1].

IgG4-related disease is a chronic fibroinflammatory condition in which immune cells infiltrate and scar tissues, and it can strike almost any organ — the pancreas, bile ducts, salivary and tear glands, kidneys, the tissue behind the abdomen and more. It often masquerades as cancer or infection, which is part of why it is under-recognised. The mainstay of treatment is glucocorticoids (steroids), which work but cause cumulative harm with long use, and relapse is common once they are stopped. A steroid-sparing, relapse-preventing drug is exactly the gap the field has been trying to fill.

What the trial did

INDIGO was a phase 3, double-blind, randomised, placebo-controlled trial sponsored by Zenas BioPharma, which is developing obexelimab [s1][s2]. It enrolled 194 patients with active IgG4-related disease and assigned them 1:1 — 97 to each group — to subcutaneous obexelimab 250 mg or placebo once weekly for 52 weeks [s1]. In both groups, glucocorticoids were tapered on a standardised schedule and stopped by week 8, so the trial tested whether the drug could hold disease in check after steroids were withdrawn [s1].

Obexelimab's mechanism is unusual. It is a bifunctional antibody that dials down B-cell activity by engaging two receptors at once — CD19 and the inhibitory receptor FcγRIIb — without destroying the B cells, in contrast to depleting antibodies such as rituximab [s1]. The primary endpoint was the time to a first disease flare that required rescue treatment, judged by both the investigator and an independent committee [s1].

What it found

Patients on obexelimab went significantly longer before flaring: the hazard ratio for a first flare requiring rescue therapy was 0.44 (95% confidence interval 0.28 to 0.71; P<.001) [s1]. In absolute terms, 26.8% of the obexelimab group flared (26 patients) versus 54.6% on placebo (53 patients) [s1]. The drug also beat placebo on every key secondary measure: complete remission at week 52 reached 37.1% versus 19.6% (P = .005), and the cumulative dose of rescue steroids was far lower — 329.5 mg versus 929.8 mg (P = .004) [s1].

Side effects were mostly manageable. Arthralgias (joint aches) were reported in 19.6% of the drug group versus 11.3% on placebo, hypersensitivity reactions in 16.5% versus 11.3%, and diarrhoea in 11.3% versus 6.2% [s1]. Serious adverse events were actually less frequent with the drug, at 10.3% versus 18.6% — a pattern that fits a treatment suppressing the underlying inflammatory disease [s1].

How to read it

The strength of INDIGO is that it is a properly controlled phase 3 trial in a disease where most prior evidence came from case series and small studies, and its results line up across the primary endpoint, remission and steroid-sparing [s1]. Cutting flares by roughly half while more than halving steroid exposure is a clinically coherent package, and the lower rate of serious events is reassuring.

The caveats are about interpretation, not credibility. The comparison was against placebo after a forced steroid taper, so the trial shows obexelimab is better than stopping treatment — not that it beats staying on steroids or using rituximab, the drugs clinicians actually reach for now [s1]. It is industry-funded, ran for one year, and enrolled fewer than 200 patients, which is substantial for a rare disease but still limits what can be said about uncommon harms or long-term durability [s1]. A reader should take this as strong evidence that the drug prevents relapse over a year, with the head-to-head questions still open.

What to watch

The practical questions now are how obexelimab compares with rituximab-based regimens, whether its benefit holds beyond a year, and how it performs across the many organs IgG4-related disease can attack. Any regulatory decision would make it the first drug approved specifically for the condition.

This article describes research and is not medical advice. Treatment of IgG4-related disease is a decision for treating clinicians.

Sources

• Obexelimab for the Treatment of IgG4-Related Disease — New England Journal of Medicine, 2 June 2026
• INDIGO trial record (NCT05662241) — ClinicalTrials.gov